Azithromycin, also known as Zithromax, belongs to the class of medicines known as antibacterials orantibiotics. These medicines kill bacteria (small organisms that can cause infection in humans) or stopbacteria from growing. Patients with weakened immune systems, includingpeople with HIV, tend to have more frequent andmore serious bacterial infections. Azithromycinwas approved by the FDA on June 14, 1996, formany uses, including the prevention and treatmentof Mycobacterium avium complex (MAC) inpersons with advanced HIV infection. It is alsobeing investigated to see how well it works inpreventing other kinds of bacterial infections inpeople with HIV.
Inspire Pharmaceuticals, Inc. announced today it has entered into an Amended and Restated License, Development and Marketing Agreement with Allergan, Inc., which revises terms related to the PROLACRIA (diquafosol tetrasodium ophthalmic solution) 2% development program and Inspire's right to receive revenues from Allergan based on net sales of RESTASIS (cyclosporine ophthalmic emulsion) 0.05% and any other human ophthalmic formulations of cyclosporine owned or controlled by Allergan.
InSite Vision Incorporated, a company developing novel ophthalmic therapeutics, today announced the initiation of a Phase 1/2 clinical trial of ISV-303, a topical anti-inflammatory product intended to reduce the pain and inflammation associated with ocular surgery. ISV-303 combines a low dose of the non-steroidal anti-inflammatory bromfenac with InSite Vision's proprietary DuraSite technology.
Single-disease initiatives in low-income countries with fragile health systems may compromise the ability of such health systems to meet the other community needs, according to a study published Tuesday in PLoS Neglected Tropical Diseases, VaccineNewsDaily.com reports (Purlain, 8/18).
If you think you shouldn't be worried about your child's—or your—lingering, nagging cough, think again. Pertussis has reemerged on the scene. In what some public health officials are calling the worst outbreak in 50 years, pertussis, better known by its unique sound—whooping cough, has been found in six states with 1,500 cases reported, six of them fatal.
Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that it has reached agreement with the United States Food and Drug Administration (FDA), under the Special Protocol Assessment (SPA) process, on the design of its planned Phase 3 study of its novel once-daily oral antibiotic Restanza to treat community acquired bacterial pneumonia (CABP). The trial is the first prospectively designed superiority study to be conducted in CABP.
Inspire Pharmaceuticals, Inc. announced today financial results for the second quarter ended June 30, 2010, reporting a net loss of $8.8 million or ($0.11) per share, an improvement from the second quarter of 2009 during which the Company incurred a net loss of $9.5 million or ($0.17) per share.
If mice are administered an antibiotic for three days and are simultaneously infected with malaria, no parasites appear in the blood and life-threatening disease is averted. In addition, the animals treated in this manner also develop robust, long-term immunity against subsequent infections. This discovery was made by the team headed by Dr. Steffen Borrmann from the Department of Infectious Diseases at Heidelberg University Hospital in cooperation with Dr. Kai Matuschewski of the Max Planck Institute for Infection Biology in Berlin. The scientists think that safe and affordable prophylaxis with antibiotics in residents of areas with high malaria transmission has the potential to be used as a natural "needle-free" vaccination against malaria.
Inspire Pharmaceuticals, Inc. announced today that data is being presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during an oral presentation and poster presentations at the 33rd Annual European Cystic Fibrosis Society (ECFS) Conference June 16 - 19, 2010 in Valencia, Spain.
Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for intellectual property that extends the current patent coverage for the Company's MultiStat family of compounds. The forthcoming patent is part of a portfolio that Quick-Med has licensed from the University of Michigan.
In a clinical trial involving HIV-negative volunteers with early-stage syphilis, researchers have found that antibiotic pills (azithromycin) are as effective as penicillin injections in curing early-stage syphilis. The study was supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced the expansion of its collaboration with the U.S. Government to include the evaluation of Restanza's activity against sexually transmitted infections (STI's), such as gonorrhea.
Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced positive results from in vitro and in vivo studies assessing the efficacy of Restanza (cethromycin), its novel oral antibiotic, against the species of Plasmodium that cause malaria.
Inspire Pharmaceuticals, Inc. announced today that Inspire scientists and collaborators will present data on denufosol tetrasodium, an investigational therapy for cystic fibrosis, during an oral presentation at the American Thoracic Society 2010 International Conference May 14 - 19, 2010 in New Orleans, LA.
Mpex Pharmaceuticals, Inc. today announced the presentation of data from its Phase 2b clinical trial with Aeroquin™ (a proprietary aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF) at the American Thoracic Society (ATS) Annual Meeting in New Orleans.
A new possible treatment to treat P. aeruginosa in cystic fibrosis patients appears to be promising, according to research to be presented at the ATS 2010 International Conference in New Orleans.
Tianyin Pharmaceutical Co., Inc.,, a biopharmaceutical company that specializes in the modernized traditional Chinese medicine and branded generics today announced fiscal results for its third quarter ended March 31, 2010.
Children and adolescents with cystic fibrosis who received the antibiotic azithromycin did not experience improved lung function, compared to patients who received placebo, according to a study in the May 5 issue of JAMA.
Inspire Pharmaceuticals, Inc. announced today financial results for the first quarter ended March 31, 2010, reporting a net loss of $14.8 million or ($0.18) per share.
Combination antibiotics effectively treat Chlamydia-induced reactive arthritis - a major step toward management, and possibly cure, of this disease, a federal multicenter clinical trial led by the University of South Florida College of Medicine found.
Researchers from University of South Florida College of Medicine found a combination of antibiotics to be an effective treatment for Chlamydia-induced reactive arthritis, a major step forward in the management, and possibly cure, of this disease. Results of this study are published in the May issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.